Clinical trials: Dyslipidemias
Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease
VT-1001 is an open-label, phase 1b, single-ascending dose study that will evaluate the safety of VERVE-101 administered to patients with heterozygous familial hypercholesterolemia (HeFH), atherosclerotic cardiovascular disease…
- Conditions
- Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Hypercholesterolemia
- Trial name
- NCT05398029
- Testing
- VERVE-101
- Where
- 3 sites in New Zealand, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Verve Therapeutics, Inc.
Hypercholesterolemia
Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia
IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK-9), preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R…
- Trial name
- NCT03815812
- Testing
- IBI306
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Hyperlipidemia
Study to Evaluate Efficacy and Safety of PreLipid® on Subjects With Higher Than Normal Blood Lipid Levels
Study to evaluate Efficacy and Safety of PreLipid® on subjects with higher than normal blood lipid levels
- Trial name
- Prelip (NCT02187757)
- Testing
- Study Dietary Supplement (Prelipid 500 mg capsules)
- Where
- 8 sites in India
- Volunteers
- 180 people
- Sponsor
- PreEmptive Meds, Pvt. Ltd
Hypertension, Dyslipidemia
A Post-marketing Surveillance to Assess Safety and Efficacy of Telostop Plus Tab.
Post-marketing surveillance of Telostop Plus Tab.
- Trial name
- NCT03648801
- Volunteers
- 600 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
The purpose of the study was to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo at Months 6 and 12 and the proportion of participants who achieve different thresholds in…
- Conditions
- Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
- Trial name
- NCT05355402
- Testing
- Olezarsen
- Where
- 24 sites in United States, Canada
- Volunteers
- 154 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypertriglyceridemia, Mixed Hyperlipidemia
A Pilot Study to Evaluate the Lipid Effects of TRIA-662
The purpose of this pilot study is to learn what study factors are important in designing a large, full-scale study of the effects of TRIA-662 on serum triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) levels.
- Trial name
- NCT02008084
- Testing
- TRIA-662
- Where
- 17 sites in Canada
- Volunteers
- 71 people
- Sponsor
- Cortria Corporation
Hypercholesterolemia, Familial, Heterozygous Familial Hypercholesterolemia
A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
The purpose of this study is to determine the pharmacokinetics of laropiprant following administration of a single dose of 1 (Panel A) and 2 (Panel B) combination tablets of MK-0524A in adolescents with heterozygous familial…
- Trial name
- NCT01583647
- Testing
- MK-0524A
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia
Effect of L. Reuteri NCIMB 30242 on Plasma Bile Acid Profile
Background: In recent years, probiotics have shown promise in treating a variety of diseases. Previously, the investigators have reported on the clinical efficacy of bile salt hydrolase active Lactobacillus reuteri NCIMB 30242 in…
- Trial name
- NCT02216825
- Testing
- Delayed release capsule, L. reuteri NCIMB 30242, escalated dose, Standard vegetarian capsule, L. reuteri NCIMB 30242, escalated dose
- Volunteers
- 10 people
- Sponsor
- Micropharma Limited
Hypercholesterolemia
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability of DC371739 Treatment in Hypercholesterolemic
This study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of DC739 after multiple-dose oral administration, to explore the clinical effective dose, and to initially explore the efficacy and safety in…
- Trial name
- NCT04927221
- Testing
- DC371739 Tablets
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Patients With Dyslipidemia
Education and Awareness Program Targeting the Assessment of Adherence of the Treatment of Dyslipidemia
Evaluate the benefit (rate of adherence to the treatment), based on the LDL-C reduction in the group that will be exposed to the program of reinforcement of orientation aimed to the patients, compared to the control group, both…
- Trial name
- PRECAVER (NCT00557778)
- Where
- Brazil
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)
Participants currently taking atorvastatin 20 mg will be switched to either atorvastatin 40 mg or ezetimibe/simvastatin 10 mg/40 mg (10/40).
- Trial name
- NCT00782184
- Testing
- ezetimibe/simvastatin 10/40, atorvastatin 40 mg, atorvastatin 20 mg
- Volunteers
- 250 people
- Sponsor
- Organon and Co
Hyperlipidemia
A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia
This is a randomized, double-blind, placebo-controlled phase 3 clinical study evaluating the long-term efficacy and safety of AK102 in patients with primary hypercholesterolemia and mixed hyperlipidemia.
- Trial name
- NCT05255458
- Testing
- AK102
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Akeso
Hypercholesterolemia
Evaluation of Crestor® (Rosuvastatin) in Daily Practice
This open label, non-interventional study is to show the efficacy of Crestor (rosuvastatin) in reduction of LDL-cholesterol and cardiovascular risk parameters in patients with hypercholesterolemia.
- Trial name
- NCT00837083
- Volunteers
- 602 people
- Sponsor
- AstraZeneca
Hypercholesteremia
A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins
The purpose of this study was to assess the efficacy, safety, and tolerability of multiple doses of gemcabene 600 mg QD compared to placebo in patients with hypercholesterolemia not adequately controlled on high-intensity or…
- Trial name
- ROYAL-1 (NCT02634151)
- Testing
- Gemcabene
- Where
- 24 sites in United States
- Volunteers
- 105 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Dyslipidemias, Pre-diabetes
Dietary Supplementation on Body Fat Composition
The purpose of the current study is to examine the effects of a dietary supplement containing plant derived phenolics at two different dose levels in otherwise generally healthy adults with risk factors (high BMI at dyslipidemia…
- Trial name
- NCT06296251
- Testing
- Plant derived phenolics
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Brightseed
Hypercholesterolaemia, Hyperlipidaemia
TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)
In patients with primary hypercholesterolemia treated with a statin and with ldl-c above the recommended target goal (esc 2003 recommendations ldl>=1.15 g/l) to compare the efficacy and the safety of ezetrol added to ongoing…
- Trial name
- NCT00328523
- Testing
- MK-0653, ezetimibe, Duration of Treatment: 3 months
- Volunteers
- 1,496 people
- Sponsor
- Organon and Co
Hypertension, Hyperlipidemia
A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin
This is a phase 1, open label, two-cohort, single-sequence, crossover study
- Trial name
- NCT02951962
- Testing
- Twynsta 80/5mg, Crestor 20mg
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Hyperlipidemia
A Study to Evaluate COR-1004 in Adult Volunteers.
This research study is being done to see if a new, injectable drug called COR-1004 is safe for people to take. It will also help doctors find the right dose of the drug.
- Trial name
- NCT07229118
- Testing
- COR-1004
- Where
- 2 sites in New Zealand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Corsera Health
Hypertension and Hyperlipidemia
Clinical Trial to Evaluate the Efficacy and Safety of YHP1701
The purpose of this study is to determine superiority of YHP1701 comparing to each monotherapy in patient with hypertension and primary hypercholesterolemia.
- Trial name
- NCT03103256
- Testing
- YHP1701, YHR1703, YHR1704
- Where
- South Korea
- Volunteers
- 106 people
- Sponsor
- Yuhan Corporation
Carotid Artery Stenosis, Hypercholesterolemia
Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects
The purpose of this study is to examine the changes in the carotid artery when subjects receive high or low doses of rosuvastatin.
- Trial name
- NCT00654394
- Testing
- Rosuvastatin
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.